In-licensing & Technical Due Diligence

For pharmaceutical companies that are looking for in-licensing compounds or patents (IP) Kinesis can perform a technical due diligence. Kinesis’ multi-disciplinary experts review the non-clinical, pharmaceutical (CMC), clinical and regulatory information that is available for the in-licensing opportunity. The strengths and weaknesses of the product, the gaps in the development program and the underlying risks will be presented. The due diligence can be completed with an estimate and planning of the studies and resources needed to develop the product. 

For pharmaceutical companies that want to out-license their assets Kinesis can assist to organize the data in such a way that a better negotiation position can be obtained in the out-licensing process.

Contact details:

Johan te Koppele, Ph.D.
Managing Director
Phone: +31 (0)6 44 53 86 37


Consultants in drug development

Print this page